UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   81-1822909
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer
    Identification No.)

 

3802 Spectrum Boulevard, Suite 112C, Tampa, Florida   33612
(Address of principal executive offices)   (Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class
to be so registered
  Name of each exchange on which
each class is to be registered
    
Common Stock,
par value $0.0001 per share
  The Nasdaq Stock Market LLC

 


If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.
 x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-255955

 

Securities to be registered pursuant to Section 12(g) of the Act:

 

None
Title of Class

 

 


 

 

 

Item 1.  Description of Registrant's Securities to Be Registered.

 

The information required by this Item is included under the captions “Description of Capital Stock” (pages 106 - 109), “Dividend Policy” (page 46) and “Shares Eligible for Future Sale” (pages 110 - 111) of the Prospectus included as part of the Registrant’s Registration Statement on Form S-1, Registration No. 333-255955 (“Form S-1”), which information is incorporated herein by this reference.

 

Item 2.  Exhibits.

 

The following documents are included as exhibits to Form S-1, as indicated, and are incorporated herein by this reference:

 

1. (a) Certificate of Incorporation of Alzamend Neuro, Inc. (Exhibit 3.1 to Form S-1).
     
  (b)

Amended and Restated Bylaws of Alzamend Neuro, Inc. (Exhibit 3.2 to Form S-1).

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

  ALZAMEND NEURO, INC.
     
Dated:   June 11, 2021 By:

/s/ Stephan Jackman

    Name: Stephan Jackman
    Title: Chief Executive Officer

 

3

 

  

EXHIBIT INDEX

 

The following documents are included as exhibits to the Registrant’s Registration Statement on Form S-1, Registration No. 333-255955, to be declared effective on June 14, 2021 (“Form S-1”), as indicated, and are incorporated herein by this reference:

 

1. (a) Certificate of Incorporation of Alzamend Neuro, Inc. (Exhibit 3.1 to Form S-1).
     
  (b)

Amended and Restated Bylaws of Alzamend Neuro, Inc. (Exhibit 3.2 to Form S-1).

 

4